Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Since its launch in late March, Mounjaro sales have trebled. Winselow Tucker, president and general manager of Lilly in India, says the drugmaker is tying up with healthcare players to spread awarenes ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...